Capital Asset Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Asset Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,543	Closed	-$212K	–	708
2021 Q2	$212K	Buy	+2,543	New	+$202K	0.02%	417
2021 Q1	–	Sell	-2,116	Closed	-$186K	–	758
2020 Q4	$186K	Buy	+2,116	New	+$168K	0.03%	350

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital Asset Advisory Services's BMRN Position: Q3 2021 in Review

Capital Asset Advisory Services sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 2,543 shares — an estimated $212K sold.

Capital Asset Advisory Services first reported a position in BMRN in Q4 2020 and held it in 2 quarters. The position peaked at $212K in Q2 2021. 511 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Capital Asset Advisory Services reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Capital Asset Advisory Services sold 2,543 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $212K.
Capital Asset Advisory Services first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 2 quarters.
Capital Asset Advisory Services's BioMarin Pharmaceuticals position peaked at $212K in Q2 2021.
511 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Capital Asset Advisory Services's 13F filing for Q3 2021, filed 14 Oct 2021.